Tardive dyskinesia (TD) is an abnormal involuntary movement disorder that arises as a common adverse effect in patients using antipsychotic medications, occurring in an estimated 20% of this population. This condition inflicts a substantial negative impact on patient quality of life and clinical outcomes and contributes to the significant rate of nonadherence to antipsychotic medication regimens.

Tardive Dyskinesia 360 is a resource center built for mental health practitioners, designed to educate providers on the proper screening, diagnosis, and treatment of TD. Explore expert video commentary, patient cases activities, instructional videos, and stay up to date on the latest information related to TD care.

Tardive Dyskinesia


AIMS Instructional Video

Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia.

From normal (0) to severe (4), see what real tardive dyskinesia movements look like so you can better assess your patients.

Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.


Andrew Cutler, MD; Stanley Caroff, MD; Caroline Tanner, MD, PhD; William Lenderking, PhD; Karen Yeomans, BSc; Huda Shalhoub, PhD; Linda Ross, MPH; Chuck Yonan, PharmD
Anita Loughlin, PhD; Nancy Lin, ScD; Victor Abler, DO; Benjamin Carroll, PharmD
Robert Farber, PhD; Donna Sparta, BS; Martha Gauthier, MA; Brooke Witherspoon, BA; Christopher O'Brien, MD; Chris Evans, PhD, MPH
Stephen Marder, MD; Robert Hauser, MD; Scott Siegert, PharmD; Clinton Wright, PharmD; Christopher O'Brien, MD
Joohi Jimenez-Shahed, MD; Stewart A. Factor, DO; William Ondo, MD; Mat D. Davis, PhD; David Stamler, MD; Robert A. Hauser, MD, MBA; Hubert H. Fernandez, MD